Replimune Group Inc
NASDAQ:REPL

Watchlist Manager
Replimune Group Inc Logo
Replimune Group Inc
NASDAQ:REPL
Watchlist
Price: 10.77 USD 3.66% Market Closed
Market Cap: 830.3m USD

EV/EBIT
Enterprise Value to EBIT

-1.6
Current
-2.1
Median
4.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1.6
=
Enterprise Value
415.5m USD
/
EBIT
-261.6m USD
EBIT Growth EV/EBIT to Growth
US
Replimune Group Inc
NASDAQ:REPL
Average EV/EBIT: 20.8
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 517.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
24
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.5 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-1.6
2-Years Forward
EV/EBIT
-1.9
3-Years Forward
EV/EBIT
-3.4